News >

Studies Continue to Evaluate Potential With Pemetrexed in NSCLC

Ellie Leick
Published: Wednesday, Jul 10, 2019

Mary Jo Fidler, MD

Mary Jo Fidler, MD

First-line treatment with pemetrexed and a platinum-based therapy followed by maintenance pemetrexed led to a 5-year overall survival (OS) rate of 11% in patients with nonsquamous non–small cell lung cancer (NSCLC), according to results of a single-center retrospective analysis.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication